Biomedica Immunoassays

Nephrology & Transplant

Biomedica offers ELISA kits for the determination of biomarkers in kidney disease. Our assay portfolio ranges from FGF23 (fibroblast growth factor 23) to Endostatin. The C4d antibody complements this product line as marker of humoral transplant rejection.

Our ELISA assays are fully validated to ensure high quality and reproducibility. Every kit includes six or seven calibrators and one or two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.  

Bone Metabolism

Biomedica offers superior quality ELISA kits for the determination of biomarkers of bone metabolism. 

Our ELISAs undergo a rigorous validation and QC process according to ICH, EMEA and FDA guidelines to ensure reproducible data. Our proprietary ELISA kits employ validated and well characterized antibodies to ensure target specificity. Every kit includes five to seven ready-to-use calibrators and one to two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.

New in our portfolio is TAmiRNA's osteomiR™ test kit, an innovative, minimally invasive test for bone quality and fracture-risk assessment detecting circulating microRNAs, obtained from a single blood specimen sample.

 

 

Cardiovascular

Biomedica offers ELISA kits for the determination of biomarkers in cardiovascular disease. Our assay portfolio ranges from natriuretic peptides, such as NT-proBNP and NT-proANP, to the Endothelins including Big ET and ET. Osteoprotegerin, a regulator of bone metabolism has evolved to a biomarker of cardiovascular disease.

Our ELISA assays are fully validated for clinical samples to ensure high quality and reproducibility. Every kit includes up to seven calibrators and one to two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.

Oxidative Stress

Biomedica's oxidative stress product line covers biomarkers for risk stratification (OxyStat and MDA-oxidized LDL) and one biomarker to determine the severity of disease (oLAB - anti oxidized LDL autoantibodies).

Our ELISA assays include six calibrators and one to two controls in human serum matrix, thus allowing researchers to collect biologically reliable data.

Nephrology & Transplant

Biomedica offers ELISA kits for the determination of biomarkers in kidney disease. Our assay portfolio ranges from FGF23 (fibroblast growth factor 23) to Endostatin. The C4d antibody complements this product line as marker of humoral transplant rejection.

Our ELISA assays are fully validated to ensure high quality and reproducibility. Every kit includes six or seven calibrators and one or two controls in a human serum matrix, thus allowing researchers to collect biologically reliable data.  

Biomedica Analytical Services

Biomedica offers a comprehensive testing service for all our proprietary ELISAs as well as kits and technologies in distribution, e.g. microRNAs and glycan profiling.

Using our analytical custom testing service, even customers without access to a fully equipped laboratory or skilled staff are able to obtain biomarker results for their samples of interest. 

Glycomics, miRNA & other Products

Biomedica is proud to be the exclusive partner of Glycotechnica offering Glycomics - Simplified Glycoanalysis in Europe. This new technology - based on LecChip™ (Lectin microarrays) - enables quick and accurate glycan profiling for any complex glycans, even for mixtures.

New in our portfolio is TAmiRNA's osteomiR™ test kit, an innovative, minimally invasive test for bone quality and fracture-risk assessment detecting circulating microRNAs, obtained from a single blood specimen sample.

Additionally, Biomedica offers the EZ4U, a non-radioactive cell proliferation and cytotoxicity assay, as well as the RFS, reagents for the elimination of rheumatoid factor in serum and plasma.